GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GeneTether Therapeutics Inc (XCNQ:GTTX) » Definitions » EV-to-Revenue

GeneTether Therapeutics (XCNQ:GTTX) EV-to-Revenue : (As of Jun. 04, 2024)


View and export this data going back to 2022. Start your Free Trial

What is GeneTether Therapeutics EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, GeneTether Therapeutics's enterprise value is C$-1.08 Mil. GeneTether Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was C$0.00 Mil. Therefore, GeneTether Therapeutics's EV-to-Revenue for today is .

The historical rank and industry rank for GeneTether Therapeutics's EV-to-Revenue or its related term are showing as below:

XCNQ:GTTX's EV-to-Revenue is not ranked *
in the Biotechnology industry.
Industry Median: 8.075
* Ranked among companies with meaningful EV-to-Revenue only.

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-06-04), GeneTether Therapeutics's stock price is C$0.02. GeneTether Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was C$0.00. Therefore, GeneTether Therapeutics's PS Ratio for today is .


GeneTether Therapeutics EV-to-Revenue Historical Data

The historical data trend for GeneTether Therapeutics's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GeneTether Therapeutics EV-to-Revenue Chart

GeneTether Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23
EV-to-Revenue
- - - -

GeneTether Therapeutics Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of GeneTether Therapeutics's EV-to-Revenue

For the Biotechnology subindustry, GeneTether Therapeutics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GeneTether Therapeutics's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, GeneTether Therapeutics's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where GeneTether Therapeutics's EV-to-Revenue falls into.



GeneTether Therapeutics EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

GeneTether Therapeutics's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=-1.082/0
=

GeneTether Therapeutics's current Enterprise Value is C$-1.08 Mil.
GeneTether Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


GeneTether Therapeutics  (XCNQ:GTTX) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

GeneTether Therapeutics's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=0.02/0
=

GeneTether Therapeutics's share price for today is C$0.02.
GeneTether Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$0.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


GeneTether Therapeutics EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of GeneTether Therapeutics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


GeneTether Therapeutics (XCNQ:GTTX) Business Description

Traded in Other Exchanges
N/A
Address
301-1665 Ellis Street, c/o Pushor Mitchell LLP, Kelowna, BC, CAN, V1Y 2B3
GeneTether Therapeutics Inc is a genetic medicines company focused on the development of high-efficiency precision gene editing for human therapeutics applications. It is engaged in creating gene-editing therapies based on the proprietary GeneTether platform. Further, it is focused on building a discovery pipeline for the treatment of rare, monogenic diseases of the kidney and the skin.

GeneTether Therapeutics (XCNQ:GTTX) Headlines

No Headlines